leanleft

opt out now

"Researchers at the Technical University of Denmark (DTU) and Lund University, Sweden, have used enzymes produced by a common gut bacteria to remove the A and B antigens from red blood cells, bringing them one step closer to creating universal donor blood."

"The most recent example is a now-merged merge request to revert an earlier change bumping the Zlib dependency for Mesa. The basis for that revert is that it breaks SPECViewPerf."

"Due to Mesa dynamically linking Zlib and how SPECViewPerf is handled, the update happens to break SPECViewPerf that is a popular benchmark for workstation graphics and one commonly used by hardware vendors and other stakeholders. Ultimately it's an issue with how SPECViewPerf is setup as an application bug but it could also be argued that Mesa could statically link it or better handle its dependencies. In any event, it's a regression for Mesa and breaks SPECViewPerf. And SPECViewPerf is important to vendors.

So the immediate solution that's now been merged is to revert that Zlib update commit..."

"They think it's a technical issue. It's not. It's a political and strategic issue for the Mesa community. If you prevent something from working that the industry finds important, you risk destroying real jobs in this community and shrinking it, regressing Mesa's reputation, making it more inferior in the industry, and thus less important. What this revert does is that it preserves existing jobs (i.e. existing stuff keeps working) and opens the door for creating new jobs and growing this community in a sustainable manner by showing others what it can do. You need capital and business interests to grow the community, and to get that, Mesa must be the best because it's always competing with alternatives.

If you thought this is only about dependencies, well, you're mistaken, and if you want to hurt the future of Mesa because your stupid zlib dependency is more important than anything else, including the livelihood of other people, you're just a foolish bikeshedder."

similar to other tools. the author says "RustViz is a bit more of a purely educational tool, as code has to be annotated manually, while Boris aims to be more of a development assistance"

it would be really great to have a lemmy client (or feature of existing client) that allows for batch downloading of a user specified list of communities.
this would allow a user to download all the content for the day or week on wifi internet and then depart from the source of internet but slowly & carefully read a selection of material(text posts, comment discussion, and even images like memes).
one benefit is that it would be extra impossible to see what users are loading/viewing because they already loaded everything and are disconnected from the internet entirely. performance is also good because there is no network latency that would be experienced, each time, when accessing the servers.

Through its savvy but legal exploitation of the U.S. patent system, Humira’s manufacturer, AbbVie, blocked competitors from entering the market. For the next six years, the drug’s price kept rising. Today, Humira is the most lucrative franchise in pharmaceutical history. AbbVie orchestrated the delay by building a formidable wall of intellectual property protection and suing would-be competitors before settling with them to delay their product launches until this year. Over the past 20 years, AbbVie and its former parent company increased Humira’s price about 30 times, most recently by 8 percent this month. Since the end of 2016, the drug’s list price has gone up 60 percent to over $80,000 a year, according to SSR Health, a research firm. AbbVie did not invent these patent-prolonging strategies; companies like Bristol Myers Squibb and AstraZeneca have deployed similar tactics to maximize profits on drugs for the treatment of cancer, anxiety and heartburn. But AbbVie’s success with Humira stands out even in an industry adept at manipulating the U.S. intellectual-property regime.

“Humira is the poster child for many of the biggest concerns with the pharmaceutical industry,” said Rachel Sachs, a drug pricing expert at Washington University in St. Louis. “AbbVie and Humira showed other companies what it was possible to do.”

Lawyers for the unnamed girl said her parents took her to Frimley Park Hospital in Surrey, southeast England, with a high fever, drowsiness, and vomiting, Metro reported. These symptoms are "red flags for meningitis and sepsis," according to the BBC News, but doctors sent her home with paracetamol, or acetaminophen.

Her parents returned to the hospital when her condition worsened, and doctors diagnosed her with meningococcal sepsis. She later experienced multi-organ failure.

The severity of her sepsis later led to her needing the quadruple-limb amputations, Elizabeth-Anne Gumbel KC, who is representing the family, said, the BBC reported. The girl had above-knee amputations of both legs, and above-elbow amputations of her arms.

Her family argued that if doctors had immediately treated her with antibiotics, she would not have been so ill and might have kept her limbs.

More than 105,000 people are on the U.S. waiting list for an organ transplant. Thousands will die before it’s their turn. Thousands more never even get put on the list, considered too much of a long shot.

“The number of organs we have available are never going to be able to meet the demand,” said Dr. Amit Tevar, a transplant surgeon at the University of Pittsburgh Medical Center. “This is our frustration.”

That’s why scientists are looking to animals as another source of organs. A Maryland man lived two months after receiving the world’s first heart transplant from a pig last January — an animal genetically modified so its organs didn’t trigger an immediate attack from the human immune system. The FDA is considering whether to allow additional xenotransplantation experiments using kidneys or hearts from gene-edited pigs.

If the Food and Drug Administration agrees, the initial experiment will be outside a patient’s body. Researchers would place a pig-turned-humanlike liver next to a hospital bed to temporarily filter the blood of someone whose own liver suddenly failed. And if that novel “liver assist” works, it would be a critical step toward eventually attempting a bioengineered organ transplant — probably a kidney.

More complex is getting human cells to take over.

“We can’t take billions of cells and push them into the organ at once,” Ross said. When slowly infused, “the cells crawl around and when they see the right environment, they stick.”

wages stagnating..